崑崙萬維(300418.SZ)子公司擬斥3000萬元投資崑崙醫雲
格隆匯2月19日丨崑崙萬維(300418.SZ)公佈，根據公司的戰略發展規劃，公司全資子公司霍爾果斯昆諾天勤創業投資有限公司(“昆諾天勤”)擬出資人民幣3000萬元投資北京崑崙醫雲科技有限公司(“崑崙醫雲”，品牌名稱為“科亞醫療”)，取得崑崙醫雲融資後2.42%的股權。北京雅惠乾灃股權投資合夥企業(有限合夥)、廣州和諧康健二期股權投資合夥企業(有限合夥)、西藏數聯投資有限公司、上海構築企業服務中心(有限合夥)等投資人共同參與此次投資。
崑崙醫雲是一家技術驅動型創新企業，專注於人工智能技術在醫療領域的應用，實現普惠醫療。崑崙醫雲將世界領先的深度學習算法和醫學影像分析算法、自然語言處理算法等技術與當前最先進的醫療理念相結合，為患者、醫療機構、生命科學研究機構提供精準診療服務。產品的應用場景覆蓋從早期篩查、精準診斷、臨牀決策支持到治療方案規劃等臨牀應用全流程，產品線包括心腦血管疾病、肺部疾病等多個方向。
崑崙醫雲歷時三年多研發的“冠脈血流儲備分數計算軟件”(“深脈分數”)，是我國第一個取得三類醫療器械註冊證的人工智能醫療產品，具有顯著的社會效益和經濟效益，是中國人工智能醫療領域的里程碑式事件。作為全球首款完全基於深度神經網絡的冠脈無創功能學評估產品，深脈分數是首個進入NMPA創新醫療器械審批綠色通道的人工智能醫療產品。目前國內尚無同品種產品註冊上市，國際僅有一款同品種產品在美國上市。與國外同類產品相比，深脈分數性能指標處於國際領先水平。
崑崙醫雲(科亞醫療)專注於人工智能技術在醫療領域的應用，致力於實現普惠醫療，自主創新研發出擁有國內首個三類醫療器械註冊證的人工智能醫療產品，具有顯著的社會效益和經濟效益，是人工智能領域的優質公司。公司投資科亞醫療，是踐行立足互聯網核心業務，投資互聯網AI(物聯網和人工智能)發展戰略的重要舉措，符合公司發展戰略。此次投資完成之後，公司2年前制定的AI+投資戰略完成了基本佈局，公司在過去2年相繼投資了AI+出行自動駕駛公司PonyAI和以色列激光雷達公司Innoviz，AI+網絡教育洋葱學院，AI+金融印度Krazybee，AI+硬件追覓科技，AI+企業服務法大大，AI+醫療科亞醫療，後續還將加大對AI+領域的持續投入。
崑崙醫雲擁有領先的技術優勢和穩定強大的核心技術團隊，能夠為公司的長期發展注入強大動力。此次交易，公正、合理地確定交易價格，不存在損害公司股東尤其是中小股東的利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
